Related Experiment Video
Updated: May 7, 2026

In vivo Assessment of Microtubule Dynamics and Orientation in Caenorhabditis elegans Neurons
Published on: November 20, 2021
Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration
David O'Sullivan1, John H Miller, Peter T Northcote
1Centre for Biodiscovery, Schools of Biological Sciences and Chemical and Physical Sciences, Victoria University of Wellington, Wellington, New Zealand.
Abstract:
We have shown previously that microtubule-stabilizing agents (MSA), a class of anti-proliferative compounds, can delay disease onset and reduce cumulative disease in an experimental model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). To explore how MSA could alter EAE disease processes, we compared the effect of administering MSA before or after peak antigen-specific proliferation and found that treatment before proliferation completely inhibited antigen-specific responses in the spleen; whereas administration of an MSA such as paclitaxel or docetaxel after peak proliferation did not. Despite the presence of antigen-specific responses in mice treated at the later time point, both treatment periods resulted in similar protection against EAE, suggesting that the protective effect of MSA in EAE could not be solely attributed to anti-proliferative activity. Instead, using in vivo migration assays, it was shown that MSA inhibit immune cell infiltration into the central nervous system (CNS). Furthermore, we found that the efficacy of an MSA could be enhanced by administering low doses of two different MSA together, such as peloruside A and ixabepilone, indicating that these MSA synergize in vivo to suppress disease. Taken together, these data suggest that MSA can suppress EAE by at least two distinct mechanisms of action--prevention of proliferation and inhibition of migration into the CNS. Finally, we have shown that a combination treatment with synergizing MSA may provide enhanced protection at lower therapeutic doses.
Insights
Microtubule-stabilizing agents (MSA) protect against experimental autoimmune encephalomyelitis (EAE) by inhibiting immune cell migration into the central nervous system (CNS) and preventing proliferation. Combination therapies with synergistic MSA enhance protection at lower doses.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Microtubule-stabilizing agents (MSA) are anti-proliferative compounds previously shown to delay disease onset and reduce cumulative disease in experimental autoimmune encephalomyelitis (EAE).
- The precise mechanisms by which MSA exert their protective effects in EAE remain incompletely understood.
Purpose of the Study:
- To investigate the mechanisms of action of MSA in EAE.
- To determine if the protective effects of MSA are solely due to their anti-proliferative activity.
- To explore the potential for synergistic effects between different MSA.
Main Methods:
- Comparison of MSA administration before or after peak antigen-specific proliferation in an EAE model.
- In vivo migration assays to assess immune cell infiltration into the central nervous system (CNS).
- Evaluation of combination therapy using different MSA (peloruside A and ixabepilone).
Main Results:
- Treatment with MSA before peak proliferation inhibited antigen-specific responses in the spleen, while treatment after peak proliferation did not.
- Despite differences in proliferation inhibition, both treatment timings resulted in similar protection against EAE.
- MSA were shown to inhibit immune cell infiltration into the CNS.
- Combination treatment with low doses of two different MSA (peloruside A and ixabepilone) enhanced efficacy and synergized in vivo.
Conclusions:
- The protective effect of MSA in EAE is not solely attributed to anti-proliferative activity.
- MSA suppress EAE through at least two mechanisms: prevention of proliferation and inhibition of immune cell migration into the CNS.
- Combination therapy with synergizing MSA offers enhanced protection at lower therapeutic doses, suggesting a promising therapeutic strategy for EAE.
More Related Videos
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
12:20Preparation of Segmented Microtubules to Study Motions Driven by the Disassembling Microtubule Ends
Published on: March 15, 2014
Related Concept Videos
Drugs that Stabilize Microtubules
Destabilization of Microtubules
Microtubule Associated Proteins (MAPs)
Drugs that Destabilize Microtubules
Microtubule Instability
Microtubules in Cell Motility